

Test Description

The MolQ Sanger Validation test confirms the variants obtained from high through put technology using sanger sequencing.

Patient Demographic

Name: Mr Sujal Raj Giri Sex: Male Date of Birth/Age: 8 years Disease: Metastatic Medullary Carcinoma of Thyroid PATIENTREPORT DATEBOOKING IDSujal Raj Giri24 Mar 2022#012202050203

Clinician

Clinician Name: Dr Amit Verma Medical Facility: Dr AV Institute of Personalized Therapy and Cancer Research (IPTCR) Pathologist: Not Provided

Specimen

Booking ID: 012202050203 Site: NA Sample Type: Blood Date of Collection: 05-02-2022 Date of Booking: 05-02-2022

CLINICAL SYNOPSIS

Mr Sujal Raj Giri, incisional biopsy from left level IV lymph node- metastatic medullary carcinoma thyroid [as per the clinical report dated 10-11-2021 provided along with the Test Requisition Form]. The tumor was identifiable in the FFPE block [2703/21]. The NGS sequencing data analysis of this patient has identified a variant in *RET* gene. The same variation is being validated by Sanger sequencing.

RESULTS

Variant is confirmed to be present by Sanger sequencing.

Analysis For: Variation in RET Gene		Gene Name: RET (Exon 13)
S.No.	Variation Detected in NGS	Sanger Validation Result
1.	chr10:g.43613906G>T; c.2370G>T; p.Leu790Phe	Present (Heterozygous)

*The variant analysis in Sanger sequencing is based on the *RET* reference sequence ENST00000355710.3¹. The exon number and nucleotide numbers will differ based on the reference file chosen and the database used.

CLINICAL CORRELATION AND VARIANT INTERPRETATION

Variant description: A missense variation in exon 13 of the *RET* gene (chr10:g.43613906G>T; c.2370G>T) that results in the amino acid substitution of Leucine for Phenylalanine at codon 790 (p.Leu790Phe) was detected in Mr Sujal Raj Giri by NGS.

The same variation was detected in heterozygous condition in this patient by Sanger sequencing (Figure 1)

atimaler Kaws

Jatinder Kaur, PhD Head, Molecular Biology & Genomics

(which a

Dr. Gulshan Yadav, MD Head, Pathology



APPENDIX 1: TEST METHODOLOGY

METHOD

Targeted gene Sanger sequencing: Exon 13 of the *RET* gene was PCR-amplified and the products were sequenced using Sanger sequencing. In case of mosaicism in leucocytes, the detection limits of Sanger sequencing for presence of variation is \sim 20%. The sequences were aligned to available reference sequences ENST00000355710.3¹ to detect variations using variant analysis software programs.


DISCLAIMER

About 0.44% of total cases are susceptible to allele dropout/dropin phenomenon, which can lead to misdiagnosis².

REFERENCES

- 1. ENSEMBL: http://www.ensembl.org.
- Blais, Jonatan *et al.* Risk of Misdiagnosis Due to Allele Dropout and False-Positive PCR Artifacts in Molecular Diagnostics. The Journal of Molecular Diagnostics, Volume 17, Issue 5, 505 514.

Figure 1: Sequence chromatogram and alignment to the reference sequence showing the variant in exon 13 of the *RET* gene (chr10:g.43613906G>T; c.2370G>T; p.Leu790Phe) detected in heterozygous condition in Mr Sujal Raj Giri.



MolQ Laboratory (A Unit of Molecular Quest Healthcare Pvt. Ltd.)

Reference Laboratory: 28-29, Sector-18 (P) | Gurgaon, Haryana, 122015 | Phone 0124 - 4307906, Fax 0124 - 4278596 | Email: contact@molq.in